News
2022-12-27
ACRO Biomedical Utilizes Innovative Collagen Ophthalmic Matrix to Save Patients from Waiting for Corneal Donation

The key core technology of ACRO Biomedical's Collagen Ophthalmic Matrix manufacturing process is to use supercritical carbon dioxide technology to decellularize porcine eyeball, and use excellent decellularization technology to make corneal scaffolds as corneal substitutes. This innovative technology replaces the traditional organic solvent process and provides the best cornea substitute.

 

The global population is facing an aging trend, and with electronic devices become more prevalent, the population with visual impairments (various types of eye lesions) is increasing day by day. According to the statistics of the World Health Organization, more than 20 million people around the world are blind due to corneal damage, and the best treatment for blindness caused by corneal damage is corneal transplantation. However, there are only about 100,000 cornea donations in the world every year, which is far less than the demand for tens of millions of corneas. In clinical practice, difficulties in preservation of fresh corneas and improper transportation also affect the quality of donated corneas. ACRO Biomedical utilizes its patented decellularization process to manufacture ABCcolla® Collagen Ophthalmic Matrix from porcine eyeballs. ABCcolla® Collagen Ophthalmic Matrix is a corneal scaffold which can be used as corneal substitutes. It can be stored dry at room temperature for up to three years, which is more convenient for transportation.

 

Supercritical Carbon Dioxide Technology Replaces Traditional Organic Solvent Process to Provide the Best Cornea Substitute

Currently, there's no competing product on the market that's similar to ABCcolla® Collagen Ophthalmic Matrix because organic solvents or surfactants are often used to remove cells in traditional manufacturing process of artificial corneas, which has a major disadvantage of incomplete removal of cells, resulting in rejection of allogeneic tissues. Organic solvent residues also could cause failure in cell attachment to rebuild the cornea. The precipitation of chemical agents may even cause secondary damage to the patient. The key core technology of ACRO Biomedical's corneal scaffold is to use supercritical carbon dioxide to remove the original host cells and impurities between the non-collagen structures from porcine eyeballs.

No chemical solvents or cross-linking agents are added to the process, which helps preserving the intact and native collagen scaffold structure in a non-recombinant manner. The clearance rate of host DNA is as high as 98.89% according to a third-party testing unit, and the product has also passed the biocompatibility test according to ISO10993, making it the safest and most effective cornea substitute.

 

Supercritical-Carbon-Dioxide-Decellularized Porcine Corneal Transplantation Has Become a New Dawn for Patients with Eye Diseases

Supercritical carbon dioxide (SCCO2) is a powerful decellularization technology. Under specific pressure and temperature, carbon dioxide has not only liquid-like fluidity, density, solubility and high mass transfer effect, but also gas-like compressibility, high diffusivity, low viscosity and molecular motion speed, which can increase the probability of molecular collision and speed up the reaction rate in the system. And because supercritical carbon dioxide has almost no surface tension, it can penetrate into porous tissues easily and has excellent cleaning and extraction effects. Based on the above characteristics, supercritical carbon dioxide is a safe, efficient and green solvent.

The porcine cornea scaffold, which has been decellularized through supercritical carbon dioxide technology, only consists of collagen structure, the original host cells have been completely removed, which can greatly reduce allergies and allogeneic tissue rejection. Its structure is exactly the same as that of the human cornea, so stem cells can quickly attach and grow and rebuild the cornea. ACRO Biomedical expects to provide patients with corneal replacement products with better quality and better effect through this patented technology, and bring a glimmer of hope to patients suffering from corneal problems around the world.

 

URL: ACRO Biomedical Utilizes Innovative Collagen Ophthalmic Matrix to Save Patients from Waiting for Corneal Donation